Compare NSIT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSIT | ADMA |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1996 | 2012 |
| Metric | NSIT | ADMA |
|---|---|---|
| Price | $107.10 | $8.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $116.25 | $25.67 |
| AVG Volume (30 Days) | 570.8K | ★ 6.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.97 | 0.19 |
| Revenue | ★ $8,247,180,000.00 | $42,219,783.00 |
| Revenue This Year | $3.79 | $27.46 |
| Revenue Next Year | $2.16 | $22.11 |
| P/E Ratio | $106.29 | ★ $41.53 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $63.62 | $7.21 |
| 52 Week High | $148.36 | $22.37 |
| Indicator | NSIT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 83.34 | 32.24 |
| Support Level | $105.78 | $7.34 |
| Resistance Level | $111.54 | $11.42 |
| Average True Range (ATR) | 4.28 | 0.32 |
| MACD | 1.91 | 0.03 |
| Stochastic Oscillator | 97.04 | 20.92 |
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.